Doctors Hail New Prostate Blood Test
Daily Post
08-25-06
NEW blood test for prostate cancer could change the way the disease is diagnosed and treated.
Not only is it far more accurate than the standard PSA test, but it can also detect cancers that have started to spread.
Researchers in the US hope the test will be available in 18 months.
Protein specific antigen or PSA is released into the blood by prostate cells.
For years, it has been relied upon as the first indicator of prostate cancer but some patients with abnormal levels are cancer- free, while others have cancers that are missed because of low readings.
The new test, developed at Johns Hopkins Medical Institutions in Baltimore, Maryland, US, looks for a different protein called early prostate cancer antigen-2, or EPCA-2.
Overall, the test identified prostate cancer patients with 94% accur acy.
In contrast, PSA levels of between four and 10 ngml detected only 85% of patients with prostate cancer.
Prostate cancer is diagnosed in about 32,000 men each year in the UK, and causes more than 10,000 deaths.
Larger clinical trials are planned that could make the new test available in the US in 18 months, said Prof Getz enberg.
Daily Post
08-25-06
NEW blood test for prostate cancer could change the way the disease is diagnosed and treated.
Not only is it far more accurate than the standard PSA test, but it can also detect cancers that have started to spread.
Researchers in the US hope the test will be available in 18 months.
Protein specific antigen or PSA is released into the blood by prostate cells.
For years, it has been relied upon as the first indicator of prostate cancer but some patients with abnormal levels are cancer- free, while others have cancers that are missed because of low readings.
The new test, developed at Johns Hopkins Medical Institutions in Baltimore, Maryland, US, looks for a different protein called early prostate cancer antigen-2, or EPCA-2.
Overall, the test identified prostate cancer patients with 94% accur acy.
In contrast, PSA levels of between four and 10 ngml detected only 85% of patients with prostate cancer.
Prostate cancer is diagnosed in about 32,000 men each year in the UK, and causes more than 10,000 deaths.
Larger clinical trials are planned that could make the new test available in the US in 18 months, said Prof Getz enberg.